Prevalence and Clinical Significance of Anti-Lactoferrin Autoantibodies in Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis

  • C. Roozendaal
  • G. Horst
  • K. Pogány
  • A. W. M. van Milligen de Wit
  • J. H. Kleibeuker
  • E. B. Haagsma
  • P. C. Limburg
  • C. G. M. Kallenberg
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 443)


Anti-neutrophil cytoplasmic antibodies (ANCA) are autoantibodies directed against cytoplasmic constituents of neutrophil granulocytes. Antibodies with specificity for protei-nase 3 and myeloperoxidase are seromarkers for systemic vasculitides. ANCA with specificity for lactoferrin were described in patients with several idiopathic inflammatory diseases, such as the inflammatory bowel diseases and rheumatoid arthritis. However, the clinical significance of anti-lactoferrin autoantibodies is still unclear.

In this study, we determined the clinical significance of anti-lactoferrin autoantibodies in sera from large groups of patients with ulcerative colitis (UC), Crohn’s disease (CD), and primary sclerosing cholangitis (PSC). Antibodies to human lactoferrin were detected by ELISA and by immunoblotting, using an extract of sonicated neutrophils as antigen source.

Autoantibodies to lactoferrin were found in 29% of patients with UC, 13% of patients with CD, and 22% of patients with PSC. In inflammatory bowel diseases, the presence of anti-lactoferrin antibodies was not related to treatment, disease activity, duration of disease, or disease extent. In PSC, the presence of autoantibodies to lactoferrin did not correlate with duration of disease or the presence of cirrhosis. However, patients with PSC and coexistent UC had significantly more frequently antibodies to lactoferrin than PSC patients without IBD.

In conclusion, autoantibodies to lactoferrin are a common feature of inflammatory bowel diseases and PSC. However, the clinical significance of those autoantibodies is limited as they lack sensitivity and specificity for those disorders. Future research should address the pathophysiological role of anti-lactoferrin ANCA and the influence of anti-lactoferrin ANCA binding on the functional properties of the lactoferrin molecule.


Inflammatory Bowel Disease Ulcerative Colitis Primary Sclerosing Cholangitis Antineutrophil Cytoplasmic Antibody Primary Sclerosing Cholangitis Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kallenberg CGM, Brouwer E, Weening JJ, Cohen Tervaert JW. Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiolical potential. Kidney Int 1994; 46: 1–15.PubMedCrossRefGoogle Scholar
  2. 2.
    Mulder AHL, Horst G, Haagsma EB, Limburg PC, Kleibeuker JH, Kallenberg CGM. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmunc liver diseases. Hepatology 1993; 17: 411–417.PubMedCrossRefGoogle Scholar
  3. 3.
    Vasiliauskas EA, Plevy SE, Landers CJ, Binder SW, Ferguson DM, Yang H. Rotter Jl, Vidrich A, Targan SR. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn’s disease define a clinical subgroup. Gastroenterology 1996; 110: 1814–1819.CrossRefGoogle Scholar
  4. 4.
    Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc 1996; 71: 431–436.PubMedCrossRefGoogle Scholar
  5. 5.
    Mulder AHL, Horst G, Van Leeuwen MA, Limburg PC, Kallenberg CGM. Anti-neutrophil cytoplasmic antibodies in rheumatoid arthritis: characterization and clinical correlates. Arthritis Rheum 1993; 36: 1054–1060.PubMedCrossRefGoogle Scholar
  6. 6.
    Afeltra A, Sebastiani GD, Galeazzi M, Caccavo D, Ferri GM, Marcolongo R, Bonomo L. Antineutrophil cytoplasmic antibodies in synovial fluid and in serum of patients with rheumatoid arthritis and other types of synovitis. J Rheumatol 1996; 23: 10–15.PubMedGoogle Scholar
  7. 7.
    Coremans IEM, Hagen EC, Daha MR, Van der Woude FJ, Van der Voort EAM, Kleyburg-Van der Keur C, Breedveld FC. Antilactoferrin antibodies in patients with rheumatoid arthritis are associated with vasculitis. Arthritis Rheum 1992; 35: 1466–1475.PubMedCrossRefGoogle Scholar
  8. 8.
    Spronk PE, Bootsma H, Horst G, Huitema MG, Limburg PC. Cohen Tervaert JW, Kallenberg CGM. Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. Br J Rheumatol 1996; 35: 625–631.PubMedCrossRefGoogle Scholar
  9. 9.
    Pozzi C, Radice, Rota S, Li Vecchi M, Sinico RA. Clinical significance of antilactoferrin antibodies in renal diseases [abstract]. Am J Kidney Dis 1991; 18: 202.Google Scholar
  10. 10.
    Sinico RA, Pozzi C, Radice A, Tincani A, Li Vecchi M, Rota S, Comotti C, Ferrario F, D’Amico G. Clinical significance of antineutrophil cytoplasmic autoantibodies with specificity for lactoferrin in renal diseases. Am J Kidney Dis 1993; 22: 253–260.PubMedGoogle Scholar
  11. 11.
    De Bandt M, Meyer O, Haim T, Kahn MF. Antineutrophil cytoplasmic antibodies in rheumatoid arthritis patients. Br J Rheumatol 1996; 35: 38–43.PubMedCrossRefGoogle Scholar
  12. 12.
    Defer MC, Follezou JY, Picard O, Damais C. Antilactoferrin autoantibodies associated with HIV infection. C R Acad Sci III 1994; 317: 675–678.PubMedGoogle Scholar
  13. 13.
    Mulder AHL, Heeringa P, Brouwer E, Limburg PC, Kallenberg CGM. Activation of granulocytes by antineutrophil cytoplasmic antibodies (ANCA): a Fc gamma RII-dependent process. Clin Exp Immunol 1994; 98: 270–278.PubMedCrossRefGoogle Scholar
  14. 14.
    Peen E, Locht H, Skogh T. IgG subclasses of lactoferrin (LF)-anti-neutrophil cytoplasmic antibodies (ANCA) [abstract]. Sarcoidosis 1996; 13: 278.Google Scholar
  15. 15.
    Peen E, Sundqvist T, Skogh T. Leucocyte activation by anti-lactoferrin antibodies bound to vascular endothelium. Clin Exp Immunol 1996; 103: 403–407.PubMedCrossRefGoogle Scholar
  16. 16.
    Van de Wiel BA, Dolman KM, Van der Meer-Gerritsen CH, Hack CD, Von dem Borne AEK, Goldschmeding R. Interference of Wegener’s granulomatosis autoantibodies with neutrophil proteinase 3 activity. Clin Exp Immunol 1992; 90: 409–414.PubMedCrossRefGoogle Scholar
  17. 17.
    Audrain MA, Gourbil A, Muller JY, Esnault LM. Anti-lactoferrin autoantibodies: relation between epitopes and iron-binding domain. J Autoimmun 1996; 9: 569–574.PubMedCrossRefGoogle Scholar
  18. 18.
    Aguas A. Esaguy N, Sunkel CE, Silva MT. Cross-reactivity and sequence homology between the 65-kilodalton mycobacterial heat shock protein and human lactoferrin, transferrin, and DR beta subsets of major histocompatibility complex class II molecules. Infect Immun 1990; 58: 1461–1470.PubMedGoogle Scholar
  19. 19.
    Esaguy N, Freitas PM, Aguas AP. Anti-lactoferrin autoantibodies in rheumatoid arthritis. Clin Exp Rheumatol 1993; 11: 581–582.PubMedGoogle Scholar
  20. 20.
    Peen E, Enestrom S, Skogh T. Distribution of lactoferrin and 60/65 kDa heat shock protein in normal and inflamed human intestine and liver. Gut 1996; 38: 135–140.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • C. Roozendaal
    • 1
  • G. Horst
    • 1
  • K. Pogány
    • 1
  • A. W. M. van Milligen de Wit
    • 2
  • J. H. Kleibeuker
    • 1
  • E. B. Haagsma
    • 1
  • P. C. Limburg
    • 1
  • C. G. M. Kallenberg
    • 1
  1. 1.Department of Internal MedicineUniversity HospitalGroningenThe Netherlands
  2. 2.Department of Gastroenterology and HepatologyAcademic Medical CentreAmsterdamThe Netherlands

Personalised recommendations